John G Ullman & Associates Inc. Sells 55,037 Shares of Pfizer Inc. (NYSE:PFE)

John G Ullman & Associates Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 352,671 shares of the biopharmaceutical company’s stock after selling 55,037 shares during the period. Pfizer comprises approximately 1.5% of John G Ullman & Associates Inc.’s portfolio, making the stock its 19th biggest position. John G Ullman & Associates Inc.’s holdings in Pfizer were worth $9,787,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. OLD National Bancorp IN increased its holdings in Pfizer by 26.2% during the 3rd quarter. OLD National Bancorp IN now owns 200,937 shares of the biopharmaceutical company’s stock worth $6,665,000 after purchasing an additional 41,679 shares in the last quarter. Tompkins Financial Corp grew its holdings in shares of Pfizer by 4.2% in the third quarter. Tompkins Financial Corp now owns 39,236 shares of the biopharmaceutical company’s stock valued at $1,301,000 after acquiring an additional 1,594 shares in the last quarter. Brown Shipley& Co Ltd grew its holdings in shares of Pfizer by 3.6% in the third quarter. Brown Shipley& Co Ltd now owns 21,200 shares of the biopharmaceutical company’s stock valued at $703,000 after acquiring an additional 746 shares in the last quarter. Comerica Bank grew its holdings in shares of Pfizer by 42.6% in the third quarter. Comerica Bank now owns 2,110,541 shares of the biopharmaceutical company’s stock valued at $70,007,000 after acquiring an additional 630,708 shares in the last quarter. Finally, Allen Mooney & Barnes Investment Advisors LLC bought a new position in shares of Pfizer in the third quarter valued at approximately $1,124,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.31 during trading on Thursday, hitting $28.66. 46,615,024 shares of the company were exchanged, compared to its average volume of 40,098,180. The company has a market cap of $162.40 billion, a PE ratio of -477.59, a P/E/G ratio of 1.10 and a beta of 0.69. The stock has a 50 day moving average of $28.23 and a 200 day moving average of $27.72. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.23 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.86%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley upped their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday. Finally, Barclays upped their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $35.69.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.